HYBRID EVENT: Join us in person in London, UK or attend virtually from anywhere.
Neoadjuvant chemotherapy represents a critical facet of cancer treatment, involving the administration of chemotherapy drugs before the main surgery or other primary interventions. The primary objective is to shrink tumors, making them more manageable or facilitating their complete removal during subsequent surgical procedures. This approach is commonly employed in the treatment of various cancers, including breast, lung, and esophageal cancers, among others.
Neoadjuvant chemotherapy offers several advantages. Firstly, it can be instrumental in reducing the size of tumors, potentially allowing for less invasive surgical procedures and preserving more healthy tissue. Additionally, this approach enables healthcare professionals to assess the tumor's response to chemotherapy, providing valuable insights into the effectiveness of the chosen treatment regimen. Neoadjuvant chemotherapy is often part of a comprehensive treatment plan, including surgery and adjuvant therapies, aimed at maximizing the chances of successful outcomes. As personalized medicine gains prominence, tailoring neoadjuvant chemotherapy regimens based on individual patient characteristics and tumor biology becomes increasingly crucial, ushering in a new era of precision oncology.
